•] Shares Ventyx Biosciences, Inc. UNDERWRITING AGREEMENTUnderwriting Agreement • October 15th, 2021 • Ventyx Biosciences, Inc. • Pharmaceutical preparations • New York
VENTYX BIOSCIENCES, INC. INDEMNIFICATION AGREEMENTIndemnification Agreement • September 29th, 2021 • Ventyx Biosciences, Inc. • Pharmaceutical preparations • Delaware
This Indemnification Agreement (this “Agreement”) is dated as of [insert date], and is between Ventyx Biosciences, Inc., a Delaware corporation (the “Company”), and [insert name of indemnitee] (“Indemnitee”).
OPEN MARKET SALE AGREEMENTSMOpen Market Sale Agreement • December 20th, 2022 • Ventyx Biosciences, Inc. • Pharmaceutical preparations • New York
VENTYX BIOSCIENCES, INC. AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT September 9, 2021Investors’ Rights Agreement • September 29th, 2021 • Ventyx Biosciences, Inc. • Pharmaceutical preparations • Delaware
THIS AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT (this “Agreement”), is made as of September 9, 2021, by and among Ventyx Bioscience, Inc., a Delaware corporation (the “Company”), and each of the investors listed on Schedule A hereto, each of which is referred to in this Agreement as an “Investor.”
FORM OF REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • March 7th, 2024 • Ventyx Biosciences, Inc. • Pharmaceutical preparations • New York
This REGISTRATION RIGHTS AGREEMENT (the “Agreement”) is made as of March 6, 2024 by and among Ventyx Biosciences, Inc., a corporation organized and existing under the laws of the State of Delaware (the “Company”), and the several purchasers signatory hereto (each, a “Purchaser” and collectively, the “Purchasers”).
VENTYX BIOSCIENCES, INC. Encinitas, CA 92024Confirmatory Employment Letter • October 15th, 2021 • Ventyx Biosciences, Inc. • Pharmaceutical preparations • California
This confirmatory employment letter agreement (the “Agreement”) is entered into between you and Ventyx Biosciences, Inc. (the “Company” or “we”), to confirm the current terms and conditions of your employment with the Company.
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • September 23rd, 2024 • Ventyx Biosciences, Inc. • Pharmaceutical preparations • New York
This Securities Purchase Agreement (this “Agreement”) is dated as of September 23, 2024, by and between Ventyx Biosciences, Inc., a Delaware corporation (the “Company”), and Aventis Inc., a company organized and existing under the laws of Pennsylvania, having registered offices at 55 Corporate Drive, Bridgewater, New Jersey 08807 (the “Purchaser”).
STANDARD MULTI-TENANT OFFICE LEASE - GROSSStandard Multi-Tenant Office Lease - Gross • October 15th, 2021 • Ventyx Biosciences, Inc. • Pharmaceutical preparations
STOCK PURCHASE AGREEMENT BY AND BETWEEN VENTYX BIOSCIENCES, INC. AND EACH OF THE PURCHASERS AS SET FORTH HEREIN MARCH 6, 2024Stock Purchase Agreement • March 7th, 2024 • Ventyx Biosciences, Inc. • Pharmaceutical preparations • Delaware
This STOCK PURCHASE AGREEMENT (this “Agreement”) is dated as of March 6, 2024, by and between Ventyx Biosciences, Inc., a Delaware corporation (the “Company”), and each of the purchasers listed on Exhibit A attached to this Agreement (each, including its successors and assigns, a “Purchaser” and together, the “Purchasers”).
CONSULTING AGREEMENTConsulting Agreement • November 7th, 2024 • Ventyx Biosciences, Inc. • Pharmaceutical preparations • California
This Consulting Agreement (this “Agreement”) is made and entered into as of April 5, 2024, by and between Ventyx Biosciences, Inc., a corporation organized under the laws of Delaware, having a principal place of business at 12790 El Camino Real, Suite 200, San Diego, CA 92130 (the “Company”), and Christopher W. Krueger, an individual with an address at [***] (“Consultant”) (each herein referred to individually as a “Party,” or collectively as the “Parties”). This Agreement will be effective as of April 15, 2024 (the “Effective Date”).
SHARE PURCHASE AGREEMENTShare Purchase Agreement • September 29th, 2021 • Ventyx Biosciences, Inc. • Pharmaceutical preparations • Delaware
This SHARE PURCHASE AGREEMENT (the “Agreement”) is made as of February 26, 2021, by and among Ventyx Biosciences, Inc., a Delaware corporation (the “Purchaser”), Zomagen Biosciences Ltd., a private company limited by shares, incorporated and registered in England and Wales with company number 11475190 whose registered office is at 125 Wood Street, London, EC2V 7AW (the “Company”), the Shareholders (as defined below) and listed on the signature pages hereto under “Shareholders”, the Noteholders (as defined below) and listed on the signature pages hereto under “Noteholders” and the SAFE Holders (as defined below) and listed on the signature pages hereto under “SAFE Holders” (the Shareholders, the Noteholders and the SAFE Holders shall be collectively referred to as the “Securityholders” and each, a “Securityholder”). The Purchaser, the Company, and the Securityholders, are sometimes referred to individually as a “Party” and collectively as the “Parties.” Certain capitalized terms that ar
May 5, 2022 William J. Sandborn, M.D. c/o Ventyx Biosciences, Inc. Re: Employment Letter Dear Bill:Employment Agreement • May 9th, 2022 • Ventyx Biosciences, Inc. • Pharmaceutical preparations • California
This employment letter agreement (the “Agreement”) is entered into between you and Ventyx Biosciences, Inc. (the “Company” or “we”), to set forth the terms and conditions of your employment with the Company.
SEPARATION AGREEMENT AND RELEASESeparation Agreement • November 7th, 2024 • Ventyx Biosciences, Inc. • Pharmaceutical preparations • Vermont
This Separation Agreement and Release (“Agreement”) is made by and between Martin D. Auster, M.D. (“Executive”) and Ventyx Biosciences, Inc. (the “Company”) (jointly referred to as the “Parties” or individually referred to as a “Party”).
EXECUTIVE CHAIRPERSON SERVICES AGREEMENTExecutive Chairperson Services Agreement • March 24th, 2022 • Ventyx Biosciences, Inc. • Pharmaceutical preparations • California
This Executive Chairperson Services Agreement (this “Agreement”) is made as of May 14, 2021 (the “Effective Date”), by and between Ventyx Biosciences, Inc., a Delaware corporation (the “Company”), and Sheila Gujrathi (the “Executive”).
Re: Employment LetterEmployment Agreement • May 16th, 2024 • Ventyx Biosciences, Inc. • Pharmaceutical preparations
This employment letter agreement (the “Agreement”) is entered into between you and Ventyx Biosciences, Inc. (the “Company” or “we”), to set forth the terms and conditions of your employment with the Company.
July 2, 2024 Mark Forman, MD, PhD [***] Via electronic mail Re: Employment Letter Dear Mark,Employment Agreement • November 7th, 2024 • Ventyx Biosciences, Inc. • Pharmaceutical preparations
This employment letter agreement (the “Agreement”) is entered into between you and Ventyx Biosciences, Inc. (the “Company” or “we”), to set forth the terms and conditions of your employment with the Company.
MASTER SERVICES AGREEMENTMaster Services Agreement • October 15th, 2021 • Ventyx Biosciences, Inc. • Pharmaceutical preparations • California
THIS MASTER SERVICES AGREEMENT (the “Agreement”) is entered into as of January 17, 2019, (the “Effective Date”) by and between VENTYX BIOSCIENCES, INC., a corporation organized under the laws of Delaware, having a principal place of business at 662 Encinitas Blvd, Suite 250, Encinitas, CA 92024, USA (“Ventyx”), and BAYSIDE PHARMA, LLC, a corporation organized under the laws of California, having a principal place of business at 2600 Hilltop Drive, B-C219, Richmond, CA 94806, USA (“BaySide”).
ASSET PURCHASE AGREEMENTAsset Purchase Agreement • September 29th, 2021 • Ventyx Biosciences, Inc. • Pharmaceutical preparations • California
This Asset Purchase Agreement (this “Agreement”), dated as of February 7, 2019 (the “Effective Date”), is entered into between Vimalan Biosciences, Inc., a Delaware corporation (“Seller”) and Ventyx Biosciences, Inc., a Delaware corporation (“Buyer”).
CONSULTING AGREEMENTConsulting Agreement • February 27th, 2024 • Ventyx Biosciences, Inc. • Pharmaceutical preparations • California
This Consulting Agreement (this “Agreement”) is made and entered into as of November 20, 2023 (the “Effective Date”) by and between Ventyx Biosciences, Inc., a corporation organized under the laws of Delaware, having a principal place of business at 12790 El Camino Real, Suite 200, San Diego, CA 92130 (the “Company”) (together with any Company Affiliate, the “Company Group”), and William J. Sandborn, M.D., an individual with an address at [***] (“Consultant”) (each herein referred to individually as a “Party,” or collectively as the “Parties”).
SEPARATION AGREEMENT AND RELEASESeparation Agreement • February 27th, 2024 • Ventyx Biosciences, Inc. • Pharmaceutical preparations • California
This Separation Agreement and Release (“Agreement”) is made by and between William J. Sandborn, M.D. (“Employee”) and Ventyx Biosciences, Inc. (the “Company”) (jointly referred to as the “Parties” or individually referred to as a “Party”).
SUBLEASE AGREEMENTSublease Agreement • July 26th, 2023 • Ventyx Biosciences, Inc. • Pharmaceutical preparations • California
THIS SUBLEASE AGREEMENT (this “Sublease”) is made and entered into this 21st day of July, 2023 (the “Effective Date”), by and between NEUROCRINE BIOSCIENCES, INC., a Delaware corporation (hereinafter referred to as the “Sublandlord”) and VENTYX BIOSCIENCES, INC., a Delaware corporation (hereinafter referred to as the “Subtenant”) (together, the “Parties”).
